Segment Wealth Management LLC Acquires Shares of 793 Amgen Inc. (NASDAQ:AMGN)

Segment Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, HoldingsChannel.com reports. The fund bought 793 shares of the medical research company’s stock, valued at approximately $228,000.

Other hedge funds also recently made changes to their positions in the company. Roundview Capital LLC boosted its position in Amgen by 1.3% during the first quarter. Roundview Capital LLC now owns 8,383 shares of the medical research company’s stock worth $2,027,000 after purchasing an additional 107 shares during the period. Merit Financial Group LLC boosted its holdings in Amgen by 39.2% in the 1st quarter. Merit Financial Group LLC now owns 2,297 shares of the medical research company’s stock worth $555,000 after buying an additional 647 shares during the period. Ergoteles LLC purchased a new position in Amgen in the 1st quarter valued at approximately $219,000. First Western Trust Bank bought a new stake in Amgen during the 1st quarter valued at $334,000. Finally, Fuller & Thaler Asset Management Inc. lifted its position in shares of Amgen by 2.1% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 24,688 shares of the medical research company’s stock worth $5,970,000 after acquiring an additional 513 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

AMGN opened at $270.36 on Wednesday. The company’s 50-day simple moving average is $283.93 and its two-hundred day simple moving average is $281.56. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72. The stock has a market capitalization of $144.89 billion, a P/E ratio of 21.65, a P/E/G ratio of 2.54 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. During the same quarter last year, the company posted $4.09 earnings per share. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. As a group, analysts predict that Amgen Inc. will post 19.48 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 3.33%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is currently 72.06%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on AMGN shares. Oppenheimer reissued an “outperform” rating and issued a $350.00 price target on shares of Amgen in a report on Thursday, February 1st. Raymond James started coverage on Amgen in a research note on Thursday, March 28th. They set a “market perform” rating for the company. StockNews.com cut Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Royal Bank of Canada restated an “outperform” rating and issued a $329.00 target price on shares of Amgen in a research report on Wednesday, April 3rd. Finally, Morgan Stanley reduced their price target on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 7th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $295.30.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.